Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 139-150

  Ruhlmann, Christina H ^a   Herrstedt, Jørn ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

aprepitant; chemotherapy induced nausea and vomiting; fosaprepitant; MK 0517; neurokinin 1; receptor antagonist

Indexed keywords

APREPITANT; CASOPITANT; DEXAMETHASONE; ETHINYLESTRADIOL; FOSAPREPITANT; GLAXOSMITHKLINE; GRANISETRON; NEUROKININ 1 RECEPTOR; NORETHISTERONE; ONDANSETRON; PLACEBO; UNCLASSIFIED DRUG; WARFARIN;

ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BINDING AFFINITY; BIOEQUIVALENCE; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; HICCUP; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; NAUSEA; NONHUMAN; REVIEW; SINGLE DRUG DOSE; THROMBOPHLEBITIS; VOMITING;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MORPHOLINES; NAUSEA; RECEPTORS, NEUROKININ-1; TREATMENT OUTCOME; VOMITING;

EID: 84856904337     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.199     Document Type: Review

References (42)

1. Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: A randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 549-558 (2009).
2. Herrstedt J, Apornwirat W, Shaharyar A et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J. Clin. Oncol. 27, 5363-5369 (2009).
3. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 21, 4112-4119 (2003). .. One of the two pivotal Phase III aprepitant trials in patients receiving highly emetogenic chemotherapy. (Pubitemid 46606178)
4. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97, 3090-3098 (2003). .. One of two pivotal Phase III aprepitant trials in patients receiving highly emetogenic chemotherapy. (Pubitemid 36676265)
5. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 23, 2822-2830 (2005). .. Pivotal Phase III aprepitant trial in patients receiving moderately emetogenic chemotherapy. (Pubitemid 46179473)
6. Coates A, Abraham S, Kaye SB et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol. 19, 203-208 (1983). (Pubitemid 13155858)
7. de Boer-Dennert M, de Wit R, Schmitz PI et al. Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists. Br. J. Cancer 76, 1055-1061 (1997). (Pubitemid 27434663)
8. Griffin AM, Butow PN, Coates AS et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol. 7, 189-195 (1996). (Pubitemid 26094884)
9. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann. Oncol. 21(Suppl. 5), v232-v243 (2010). . Most recently updated and clinically applicable antiemetic guidelines. 10 Maggi CA. The mammalian tachykinin receptors. Gen. Pharmacol. 26, 911-944 (1995).
10. Andrews PL, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 32, 799-806 (1993). (Pubitemid 23227666)
11. Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav. Brain Res. 11, 277-281 (1984).
12. Snider RM, Constantine JW, Lowe JA III et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251, 435-437 (1991). (Pubitemid 21916907)
13. Hale JJ, Mills SG, MacCoss M et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J. Med. Chem. 43, 1234-1241 (2000). (Pubitemid 30173749)
14. Huskey SE, Dean BJ, Doss GA et al. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab. Dispos. 32, 246-258 (2004). (Pubitemid 38176943)
15. Huskey SE, Dean BJ, Bakhtiar R et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab. Dispos. 31, 785-791 (2003). (Pubitemid 36617669)
16. Bergstrom M, Hargreaves RJ, Burns HD et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry 55, 1007-1012 (2004). (Pubitemid 38581916)
17. Huskey SE, Luffer-Atlas D, Dean BJ et al. Substance P receptor antagonist I: Conversion of phosphoramidate prodrug after i.v. administration to rats and dogs. Drug Metab. Dispos. 27, 1367-1373 (1999).
18. Lasseter KC, Gambale J, Jin B et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J. Clin. Pharmacol. 47, 834-840 (2007).
19. Sanchez RI, Wang RW, Newton DJ et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab. Dispos. 32, 1287-1292 (2004). (Pubitemid 39410914)
20. Majumdar AK, Howard L, Goldberg MR et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol. 46, 291-300 (2006). (Pubitemid 43260316)
21. Tattersall FD, Rycroft W, Cumberbatch M et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39, 652-663 (2000). (Pubitemid 30089315)
22. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N. Engl. J. Med. 340, 190-195 (1999). (Pubitemid 29063215)
23. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. 19, 1759-1767 (2001). (Pubitemid 32230878)
24. Cocquyt V, Van BS, Reinhardt RR et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer 37, 835-842 (2001). (Pubitemid 32323960)
25. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 94, 3032-3041 (2002). (Pubitemid 34547705)
26. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97, 2290-2300 (2003). (Pubitemid 36444075)
27. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer 18, 423-431 (2010).
28. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann. Oncol. 17, 1000-1006 (2006). (Pubitemid 43778994)
29. Grunberg S, Chua D, Maru A et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol - EASE. J. Clin. Oncol. 29, 1495-1501 (2011). .. Only Phase III fosaprepitant trial and, moreover, the largest antiemetic trial conducted to date.
30. de Wit R, Herrstedt J, Rapoport B et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: A combined analysis of two randomised, placebo-controlled Phase III clinical trials. Eur. J. Cancer 40, 403-410 (2004). (Pubitemid 38121278)
31. Herrstedt J, Muss HB, Warr DG et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104, 1548-1555 (2005). (Pubitemid 41356171)
32. Ruhlmann CH, Herrstedt J. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin. Drug Saf. 10, 449-462 (2011).
33. McCrea JB, Majumdar AK, Goldberg MR et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol. Ther. 74, 17-24 (2003). (Pubitemid 36776172)
34. Marbury TC, Ngo PL, Shadle CR et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J. Clin. Pharmacol. 51(12), 1712-1720 (2011).
35. Depre M, Van HA, Oeyen M et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur. J. Clin. Pharmacol. 61, 341-346 (2005). (Pubitemid 41569307)
36. Arpornwirat W, Albert I, Hansen VL et al. Phase II trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115, 5807-5816 (2009).
37. Roila F, Rolski J, Ramlau R et al. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann. Oncol. 20, 1867-1873 (2009).
38. Rudd J, Ngan MP, Cantoreggi S, Pietra C. The co-administration of the NK1 receptor antagonist netupitant with palonosetron and dexamethasone reduces cisplatin-induced acute and delayed emesis in ferrets. Support Care Cancer 19(Suppl. 2), S155 (2011).
39. Hesketh PJ, Sanz-Altamira P, Bushey J, and Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer doi:10.1007/s00520-011-1180-2 (2011) (Epub ahead of print).
40. Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer 19, 2063-2066 (2011).
41. Hesketh PJ, Wright O, Rosati G et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: A multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer doi:10.1007/s00520-011-1235-4 (2011) (Epub ahead of print).
42. Martin M, Diaz-Rubio E, Sánshez A, Almenarez J, Lopez-Vega M. The natural course of emesis after carboplatin treatment. Acta. Oncol. 29, 593-595 (1990). (Pubitemid 20294735)